Regarding to FCARH143 trial, the authors reported a patient who relapsed presenting a BCMAnegative myeloma subclone and an overall reduction of 70% BCMA expression level in the BCMApositive myeloma cell population (35). Here, TNFRSF17 is linked to plasma cell myeloma.